Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Transplantation. 2019 Jan;103(1):168–176. doi: 10.1097/TP.0000000000002417

Figure 2: Development of peripheral blood mixed chimerism after DBMT.

Figure 2:

Excellent hematopoietic chimerism was induced in both myeloid (A) and lymphoid (B) lineages in all recipients treated with the aCD40/Bela/hATG regimen (closed circle). The levels of chimerism were significantly superior to those observed in previous studies of belatacept-based regimens (Bela/hATG: open circle1 or Bela/rATG: open square2). *: p<0.05, **: p<0.01.